Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 6/20 | 0.59 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.59 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21992360 | 1.00 | SLC1A1 (0.59) | SLC1A1SLC1A3SLC1A2MEN1CYP1A2 | |
| SCHEMBL21992356 | 0.88 | SLC1A1 (0.49) | SLC1A1SLC1A3SLC1A2MEN1CYP1A2 | |
| SCHEMBL30989122 | 0.84 | SLC1A1 (0.56) | SLC1A1SLC1A3SLC1A2MEN1CYP1A2 | |
| SCHEMBL22247084 | 0.84 | SLC1A1 (0.59) | SLC1A1SLC1A3SLC1A2MEN1CYP1A2 | |
| SCHEMBL418322 | 0.82 | SLC1A3 (0.76) | SLC1A1SLC1A3SLC1A2MEN1CYP1A2 | |
| SCHEMBL852209 | 0.82 | SLC1A3 (0.76) | SLC1A1SLC1A3SLC1A2MEN1CYP1A2 | |
| SCHEMBL1953602 | 0.82 | SLC1A3 (0.76) | SLC1A1SLC1A3SLC1A2MEN1CYP1A2 | |
| SCHEMBL9254953 | 0.82 | SLC1A2 (0.61) | SLC1A1SLC1A3SLC1A2MEN1CYP1A2 | |
| SCHEMBL13173217 | 0.82 | SLC1A2 (0.61) | SLC1A1SLC1A3SLC1A2MEN1CYP1A2 | |
| SCHEMBL21580352 | 0.82 | SLC1A1 (0.66) | SLC1A1SLC1A3SLC1A2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175808-A1 | GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-11197877-B2 | Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists | GLYCOMIMETICS. INC. (US) | 2021-12-14 | — | — | US | disclosed |
| WO-2020150263-A1 | SELECTIN OR GALECTIN ANTAGONISTS FOR TREATING CYTOKINE RELEASE SYNDROME AND CRS-INDUCED NEUROTOXICITY | MAGNANI JOHN L (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200129536-A1 | GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175808-A1 | GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTS | SELE, SELPLG, SELP | SLC1A1 2046/4885SLC1A3 2304/4885SLC1A2 2303/4885 |
| US-11197877-B2 | Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists | SELE, SELPLG, SELP | SLC1A1 2202/4885SLC1A3 2556/4885SLC1A2 2517/4885 |
| US-20200129536-A1 | GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTS | SELE, SELPLG, SELP | SLC1A1 2046/4885SLC1A3 2304/4885SLC1A2 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.